Shots:

• The EMA's CHMP has adopted a positive opinion recommending the marketing authorization for Wegovy in adults with obesity in chronic weight management in adults with obesity
• The approval is based on P-IIIa (STEP) study evaluating Wegovy (2.4mg injection, qw) in ~4,500 adults with obesity or overweight with one weight-related comorbidity. The results showed 17-18% average weight loss in people without T2D @68wks. and has a safe & well-tolerated profile across the program
• The company is expected to receive final EC marketing authorization in ~2mos  & Wegovy is expected to launch in EU by H2'22. In Jun'21, Wegovy has received the US FDA's approval & was launched in the US

 Ref: Globe Newswire | Image: Novo Nordisk